{"id":477995,"date":"2020-04-06T13:36:01","date_gmt":"2020-04-06T13:36:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477995"},"modified":"2020-04-06T13:36:01","modified_gmt":"2020-04-06T13:36:01","slug":"ataxia-telangiectasia-epidemiology-forecast-to-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ataxia-telangiectasia-epidemiology-forecast-to-2030_477995.html","title":{"rendered":"Ataxia Telangiectasia Epidemiology Forecast to 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1586173672.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Ataxia Telangiectasia Epidemiology Forecast to 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1586173672.jpeg\" alt=\"Ataxia Telangiectasia Epidemiology Forecast to 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Ataxia Telangiectasia Epidemiology<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s \u201cAtaxia Telangiectasia Epidemiology Forecast to 2030\u201d report delivers an in-depth understanding of the disease, historical and forecasted Ataxia Telangiectasia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p><\/div>\n<p style=\"text-align: justify;\">(Albany, US) DelveInsight launched a new report on <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ataxia-telangiectasia-at-epidemiology-forecast\">Ataxia Telangiectasia Epidemiology Forecast to 2030<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the report:-<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Ataxia Telangiectasia occurs in 1 in 40,000&ndash;100,000 people worldwide.<br \/> 2. Males and females are affected in equal numbers. In the United States, the prevalence is approximately 1 in 40,000&ndash;100,000 live births.<br \/> 3. In the United States, about one per cent of the population is a carrier of a mutation in the Ataxia Telangiectasia mutated kinase (ATM) gene.<br \/> 4. The average Ataxia Telangiectasia prevalence is 1 per 100,000 children. The most reliable estimates for the number of people with Ataxia Telangiectasia, in the UK at least are 3 per million.<\/p>\n<p style=\"text-align: justify;\">Request for sample pages:- <a rel=\"nofollow\" href=\"https:\/\/delveinsight.com\/sample-request\/ataxia-telangiectasia-at-epidemiology-forecast\">https:\/\/delveinsight.com\/sample-request\/ataxia-telangiectasia-at-epidemiology-forecast<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Ataxia Telangiectasia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns<\/li>\n<li>The Ataxia Telangiectasia Epidemiology Report and Model provide an overview of the risk factors and global trends of Ataxia Telangiectasia in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)<\/li>\n<li>The report provides insight about the historical and forecasted patient pool of Ataxia Telangiectasia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan<\/li>\n<li>The report helps to recognize the growth opportunities in the 7MM with respect to the patient population<\/li>\n<li>The report assesses the disease risk and burden and highlights the unmet needs of Ataxia Telangiectasia .<\/li>\n<li>The report provides the segmentation of the Ataxia Telangiectasia epidemiology<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/7541835671974c4513b819bf32024b76.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Reasons to buy<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Ataxia Telangiectasia Epidemiology report will allow the user to &#8211;<\/li>\n<li>Develop business strategies by understanding the trends shaping and driving the global Ataxia Telangiectasia market<\/li>\n<li>Quantify patient populations in the global Ataxia Telangiectasia market to improve product design, pricing, and launch plans<\/li>\n<li>Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Ataxia Telangiectasia therapeutics in each of the markets covered<\/li>\n<li>Understand the magnitude of Ataxia Telangiectasia population by its epidemiology<\/li>\n<li>The Ataxia Telangiectasia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Request for sample pages:- <a rel=\"nofollow\" href=\"https:\/\/delveinsight.com\/sample-request\/ataxia-telangiectasia-at-epidemiology-forecast\">https:\/\/delveinsight.com\/sample-request\/ataxia-telangiectasia-at-epidemiology-forecast<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<strong>Table of contents <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1.&nbsp;Key Insights<\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>2. Executive Summary of <\/strong>Ataxia Telangiectasia<\/p>\n<p style=\"text-align: justify;\"><strong>3.&nbsp;<\/strong>Ataxia Telangiectasia <strong>Disease Background and Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">3.1.&nbsp;Introduction<\/p>\n<p style=\"text-align: justify;\">3.2.&nbsp;Sign and Symptoms<\/p>\n<p style=\"text-align: justify;\">3.3.&nbsp;Pathophysiology<\/p>\n<p style=\"text-align: justify;\">3.4.&nbsp;Risk Factors<\/p>\n<p style=\"text-align: justify;\">3.5.&nbsp;Diagnosis<\/p>\n<p style=\"text-align: justify;\"><strong>4.&nbsp;Patient Journey<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>5.&nbsp;Epidemiology and Patient Population<\/strong><\/p>\n<p style=\"text-align: justify;\">5.1.&nbsp;Epidemiology Key Findings<\/p>\n<p style=\"text-align: justify;\">5.2.&nbsp;Assumptions and Rationale: 7MM<\/p>\n<p style=\"text-align: justify;\"><strong>5.3.&nbsp;Epidemiology Scenario: 7MM<\/strong><\/p>\n<p style=\"text-align: justify;\">5.3.1.&nbsp;Ataxia Telangiectasia Epidemiology Scenario in the 7MM (2017- 2030)<\/p>\n<p style=\"text-align: justify;\"><strong>5.4.&nbsp;United States Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">5.4.1.&nbsp;Ataxia Telangiectasia Epidemiology Scenario in the United States (2017- 2030)<\/p>\n<p style=\"text-align: justify;\"><strong>5.5.&nbsp;EU-5 Country-wise Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">5.5.1. Germany Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.5.1.1.&nbsp;Ataxia Telangiectasia Epidemiology Scenario in Germany (2017- 2030)<\/p>\n<p style=\"text-align: justify;\">5.5.2. France Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.5.2.1.&nbsp;Ataxia Telangiectasia Epidemiology Scenario in France (2017- 2030)<\/p>\n<p style=\"text-align: justify;\">5.5.3. Italy Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.5.3.1.&nbsp;Ataxia Telangiectasia Epidemiology Scenario in Italy (2017- 2030)<\/p>\n<p style=\"text-align: justify;\">5.5.4. Spain Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.5.4.1.&nbsp;Ataxia Telangiectasia Epidemiology Scenario in Spain (2017- 2030)<\/p>\n<p style=\"text-align: justify;\">5.5.5. United Kingdom Epidemiology<\/p>\n<p style=\"text-align: justify;\">5.5.5.1.&nbsp;Ataxia Telangiectasia Epidemiology Scenario in the United Kingdom (2017-2030)<\/p>\n<p style=\"text-align: justify;\"><strong>5.6. Japan Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">5.6.1.&nbsp;Ataxia Telangiectasia Epidemiology Scenario in Japan (2017- 2030)<\/p>\n<p style=\"text-align: justify;\"><strong>6.&nbsp;Treatment Algorithm, Current Treatment, and Medical Practices<\/strong><\/p>\n<p style=\"text-align: justify;\">6.1.&nbsp;Ataxia Telangiectasia Treatment and Management<\/p>\n<p style=\"text-align: justify;\">6.2.&nbsp;Ataxia Telangiectasia Treatment Algorithm<\/p>\n<p style=\"text-align: justify;\"><strong>7.&nbsp;KOL Views<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>8.&nbsp;Unmet Needs<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>9.&nbsp;&nbsp;Appendix<\/strong><\/p>\n<p style=\"text-align: justify;\">9.1.&nbsp;Bibliography<\/p>\n<p style=\"text-align: justify;\">9.2.&nbsp;Report Methodology<\/p>\n<p style=\"text-align: justify;\"><strong>10.&nbsp;DelveInsight Capabilities<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>11.&nbsp;Disclaimer<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>12.&nbsp;About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Related reports :-<\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ataxia-telangiectasia-at-pipeline-insight\" target=\"_blank\"><em><strong>Ataxia<\/strong><\/em><strong>&nbsp;<\/strong><em><strong>Telangiectasia<\/strong><\/em><strong>&nbsp;(AT) &#8211; Pipeline Insights, 2020<\/strong><\/a><\/p>\n<p class=\"posttext\" style=\"text-align: justify;\">Ataxia Telangiectasia (AT) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Ataxia Telangiectasia (AT) market.<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ataxia-telangiectasia-at-market\" target=\"_blank\"><em><strong>Ataxia<\/strong><\/em><strong>&nbsp;<\/strong><em><strong>Telangiectasia<\/strong><\/em><strong>&nbsp;(AT) Market Insight, Epidemiology and Market Forecast -2030<\/strong><\/a><\/p>\n<p class=\"posttext\" style=\"text-align: justify;\">DelveInsight&#8217; s Ataxia Telangiectasia (AT) &#8211; Market Insights, Epidemiology and Market Forecast &#8211; 2030 report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=ataxia-telangiectasia-epidemiology-forecast-to-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=ataxia-telangiectasia-epidemiology-forecast-to-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ataxia Telangiectasia Epidemiology DelveInsight&#8217;s \u201cAtaxia Telangiectasia Epidemiology Forecast to 2030\u201d report delivers an in-depth understanding of the disease, historical and forecasted Ataxia Telangiectasia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/ataxia-telangiectasia-epidemiology-forecast-to-2030_477995.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-477995","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477995","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=477995"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477995\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=477995"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=477995"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=477995"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}